Found: 15
Select item for more details and to access through your institution.
Phosphoproteomic Landscape of AML Cells Treated with the ATP-Competitive CK2 Inhibitor CX-4945.
- Published in:
- Cells (2073-4409), 2021, v. 10, n. 2, p. 338, doi. 10.3390/cells10020338
- By:
- Publication type:
- Article
Systemic administration of a peptide that impairs the protein kinase (CK2) phosphorylation reduces solid tumor growth in mice.
- Published in:
- International Journal of Cancer, 2008, v. 122, n. 1, p. 57, doi. 10.1002/ijc.23013
- By:
- Publication type:
- Article
CIGB-300 anticancer peptide regulates the protein kinase CK2-dependent phosphoproteome.
- Published in:
- Molecular & Cellular Biochemistry, 2020, v. 470, n. 1/2, p. 63, doi. 10.1007/s11010-020-03747-1
- By:
- Publication type:
- Article
Preclinical efficacy of CIGB-300, an anti-CK2 peptide, on breast cancer metastasic colonization.
- Published in:
- Scientific Reports, 2020, v. 10, n. 1, p. N.PAG, doi. 10.1038/s41598-020-71854-6
- By:
- Publication type:
- Article
Safety and preliminary efficacy data of a novel Casein Kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies.
- Published in:
- BMC Cancer, 2009, v. 9, p. 1, doi. 10.1186/1471-2407-9-146
- By:
- Publication type:
- Article
CIGB-300 Anticancer Peptide Differentially Interacts with CK2 Subunits and Regulates Specific Signaling Mediators in a Highly Sensitive Large Cell Lung Carcinoma Cell Model.
- Published in:
- Biomedicines, 2023, v. 11, n. 1, p. 43, doi. 10.3390/biomedicines11010043
- By:
- Publication type:
- Article
Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300.
- Published in:
- Biomedicines, 2021, v. 9, n. 7, p. 766, doi. 10.3390/biomedicines9070766
- By:
- Publication type:
- Article
Characterization of low-abundance species in the active pharmaceutical ingredient of CIGB-300: A clinical-grade anticancer synthetic peptide.
- Published in:
- Journal of Peptide Science, 2018, v. 24, n. 6, p. 1, doi. 10.1002/psc.3081
- By:
- Publication type:
- Article
Sensitivity of tumor cells towards CIGB-300 anticancer peptide relies on its nucleolar localization.
- Published in:
- Journal of Peptide Science, 2012, v. 18, n. 4, p. 215, doi. 10.1002/psc.1432
- By:
- Publication type:
- Article
Clinical-Grade Peptide-Based Inhibition of CK2 Blocks Viability and Proliferation of T-ALL Cells and Counteracts IL-7 Stimulation and Stromal Support.
- Published in:
- Cancers, 2020, v. 12, n. 6, p. 1377, doi. 10.3390/cancers12061377
- By:
- Publication type:
- Article
The synthetic peptide CIGB-300 modulates CK2-dependent signaling pathways affecting the survival and chemoresistance of non-small cell lung cancer cell lines.
- Published in:
- Cancer Cell International, 2017, v. 17, p. 1, doi. 10.1186/s12935-017-0413-y
- By:
- Publication type:
- Article
Synergistic interactions of the anti-casein kinase 2 CIGB-300 peptide and chemotherapeutic agents in lung and cervical preclinical cancer models.
- Published in:
- Molecular & Clinical Oncology, 2014, v. 2, n. 6, p. 935, doi. 10.3892/mco.2014.338
- By:
- Publication type:
- Article
CIGB-300 Peptide Targets the CK2 Phospho-Acceptor Domain on Human Papillomavirus E7 and Disrupts the Retinoblastoma (RB) Complex in Cervical Cancer Cells.
- Published in:
- Viruses (1999-4915), 2022, v. 14, n. 8, p. 1681, doi. 10.3390/v14081681
- By:
- Publication type:
- Article
Targeting of Protein Kinase CK2 Elicits Antiviral Activity on Bovine Coronavirus Infection.
- Published in:
- Viruses (1999-4915), 2022, v. 14, n. 3, p. 552, doi. 10.3390/v14030552
- By:
- Publication type:
- Article
Gene expression profiling unveils the temporal dynamics of CIGB-300-regulated transcriptome in AML cell lines.
- Published in:
- BMC Genomics, 2023, v. 24, n. 1, p. 1, doi. 10.1186/s12864-023-09472-5
- By:
- Publication type:
- Article